Brought to you by 
Series B round brings in $48.5mm for Concert Pharmaceuticals
28 Feb 2013
Executive Summary
Concert Pharmaceuticals (developing therapeutics for cancer, diabetes, and cardiovascular conditions) has closed its $48.5mm Series B venture round. Lead investor Flagship Ventures was joined by fellow new backers Brookside Capital Partners and New Leaf Venture Partners as well as current shareholders Three Arch Partners, TVM Capital, Skyline Ventures, Greylock Partners, and QVT Fund. A representative from Flagship will take a seat on the company's board.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series B round brings in $48.5mm for Concert Pharmaceuticals
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice